- Home
- NUS vs ETON Comparison
NUS vs ETON Comparison
Compare NUS & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUS
- ETON
- Stock Information
- Founded
- NUS 1984
- ETON 2017
- Country
- NUS United States
- ETON United States
- Employees
- NUS N/A
- ETON N/A
- Industry
- NUS Other Pharmaceuticals
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- NUS Health Care
- ETON Health Care
- Exchange
- NUS Nasdaq
- ETON Nasdaq
- Market Cap
- NUS 321.6M
- ETON 329.8M
- IPO Year
- NUS 1996
- ETON 2018
- Fundamental
- Price
- NUS $8.13
- ETON $15.58
- Analyst Decision
- NUS Hold
- ETON Strong Buy
- Analyst Count
- NUS 2
- ETON 3
- Target Price
- NUS $6.88
- ETON $24.00
- AVG Volume (30 Days)
- NUS 888.5K
- ETON 244.0K
- Earning Date
- NUS 05-07-2025
- ETON 05-08-2025
- Dividend Yield
- NUS 2.96%
- ETON N/A
- EPS Growth
- NUS N/A
- ETON N/A
- EPS
- NUS N/A
- ETON N/A
- Revenue
- NUS $1,732,084,000.00
- ETON $34,677,000.00
- Revenue This Year
- NUS N/A
- ETON $22.19
- Revenue Next Year
- NUS N/A
- ETON $109.55
- P/E Ratio
- NUS N/A
- ETON N/A
- Revenue Growth
- NUS N/A
- ETON 5.64
- 52 Week Low
- NUS $5.95
- ETON $3.03
- 52 Week High
- NUS $14.04
- ETON $18.41
- Technical
- Relative Strength Index (RSI)
- NUS 59.47
- ETON 53.40
- Support Level
- NUS $7.81
- ETON $14.28
- Resistance Level
- NUS $8.38
- ETON $15.02
- Average True Range (ATR)
- NUS 0.37
- ETON 0.93
- MACD
- NUS -0.01
- ETON -0.00
- Stochastic Oscillator
- NUS 75.25
- ETON 79.52
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.